biolog
mass
spectrometri
evolv
core
analyt
technolog
last
decad
mainli
unparallel
abil
perform
qualit
well
quantit
profil
enorm
complex
biolog
sampl
high
mass
accuraci
sensit
select
specif
mass
spectrometrybas
techniqu
also
routin
use
assess
glycosyl
posttransl
modif
disulfid
bond
linkag
scrambl
well
detect
host
cell
protein
contamin
field
biopharmaceut
role
mass
spectrometri
vaccin
develop
limit
expand
landscap
global
vaccin
develop
shift
toward
develop
recombin
vaccin
review
role
mass
spectrometri
vaccin
develop
present
ongo
effort
develop
vaccin
diseas
global
unmet
medic
need
discuss
regulatori
challeng
implement
mass
spectrometri
techniqu
qualiti
control
laboratori
set
highlight
k
e
w
r
envelop
protein
glycan
glycopeptid
glycoprotein
idm
malditof
ms
im
rplcm
vaccin
target
popul
vaccin
healthi
individu
pregnant
women
infant
vaccin
safeti
paramount
import
appropri
vaccin
landscap
chang
tradit
vaccin
approach
costeffect
highli
scalabl
safe
recombin
vaccin
use
recombin
dna
technolog
antigen
express
yeast
escherichia
coli
baculoviru
express
vector
system
bev
mammalian
cell
line
recombin
antigen
engin
mimic
first
step
viru
attach
cell
surfac
mediat
specif
glycoprotein
express
recombin
antigen
undergo
multipl
purif
cycl
produc
highli
purifi
vaccin
order
recombin
vaccin
accept
regulatori
author
indepth
analyt
character
need
perform
review
focu
expand
role
mass
spectrometri
vaccin
develop
irrespect
rout
product
also
highlight
regulatori
challeng
limit
mass
spectrometrybas
techniqu
constrain
implement
qualiti
control
batch
releas
assay
cgmp
manufactur
role
mass
spectrometri
altern
olink
glycan
form
link
oligosaccharid
serin
threonin
residu
glycosyl
play
fundament
role
antigen
conform
fold
stabil
solubl
importantli
immun
respons
plant
yeast
nonhuman
cell
line
gener
glycan
compat
bioactiv
within
human
host
thu
recombin
glycoprotein
produc
mammalianbas
express
system
chines
hamster
ovari
cho
cell
analyt
character
glycoprotein
challeng
inher
unpredict
associ
glycan
either
macroheterogen
potenti
glycan
site
protein
glycosyl
microheterogen
differ
glycan
structur
found
site
express
protein
glycosyl
analysi
perform
understand
natur
structur
heterogen
glycan
quantifi
importantli
determin
glycosyl
occur
site
specif
analysi
mass
spectrometri
base
techniqu
valuabl
tool
detect
investig
glycosyl
figur
although
msbase
glycosyl
analysi
without
limit
advanc
ms
instrument
glycan
analysi
softwar
led
increas
resolut
autom
identif
quantit
determin
accur
structur
character
anoth
critic
qualiti
attribut
cqa
glycoprotein
intramolecular
disulfid
bond
ss
linkag
ensur
correct
fold
function
activ
stabil
incorrect
format
disulfid
bond
caus
protein
misfold
tend
promot
aggreg
could
result
unwarr
immun
respons
confirm
correct
disulfid
bond
format
recombin
first
studi
analyz
sitespecif
nglycosyl
report
describ
structur
character
express
revers
phase
hplc
tryptic
digest
peptid
collect
rphplc
identifi
amino
acid
analysi
aaa
ntermin
sequenc
analysi
leonard
et
al
express
cho
cell
mass
spectrometr
character
glycosyl
pattern
maldi
nanoesilcmsm
use
hybrid
quadrupoletimeofflight
tandem
mass
spectromet
qtof
use
assign
glycosyl
site
zhu
et
al
hiv
jrfl
con
env
express
cho
cell
glycopeptidebas
mass
map
approach
use
character
glycosyl
two
env
protein
vaccin
candid
glycosyl
sitespecif
fashion
mass
spectrometri
base
approach
use
map
complet
glycosyl
profil
everi
site
eleven
env
trimer
highresolut
lcmsm
perform
use
orbitrap
velo
pro
hybrid
mass
spectromet
thermo
scientif
equip
etd
coupl
acquiti
uplc
system
water
go
et
al
hiv
monom
sosip
global
nglycan
site
occup
metabol
engin
highresolut
intact
mass
spectrometri
perform
releas
nglycan
analysi
carri
use
synapt
ion
mobil
mass
spectromet
nativ
highresolut
mass
spectrometri
perform
q
exact
hybrid
quadrupoleorbitrap
mass
spectromet
illustr
follow
section
tabl
mass
spectrometrybas
techniqu
use
perform
structur
character
glycosyl
profil
antigen
quantit
develop
hiv
influenza
dengu
ebola
meningococc
vaccin
review
also
highlight
mass
spectrometrybas
method
glycan
analysi
use
analyz
specif
envelop
glycoprotein
env
broad
applic
glycoproteinbas
vaccin
quest
safe
effect
vaccin
protect
human
one
hypothes
explor
protect
immun
hiv
induc
broadli
neutral
antibodi
bnab
target
highli
glycosyl
virionassoci
envelop
number
approach
pursu
vaccin
develop
field
establish
protect
immun
includ
monomer
subunit
oligomer
trimer
envelop
glycoprotein
elicit
bnab
envelop
env
immunogen
multipl
expos
epitop
heterogen
glycosyl
molecul
mass
consist
glycan
nlink
glycan
critic
import
monitor
hiv
env
glycan
shield
vaccin
develop
crispin
collabor
also
extens
investig
nativ
glycosyl
profil
env
particularli
trimer
immunogen
studi
led
increas
understand
glycan
shield
env
larg
accept
induc
bnab
hiv
vaccin
candid
glycan
profil
similar
one
present
nativ
env
trimer
thorough
studi
trimer
env
glycosyl
behren
et
al
influenza
viru
segment
envelop
rna
viru
among
icidmsmrm
method
truli
altern
approv
srid
method
dual
purpos
potenc
content
determin
found
equival
srid
method
also
use
respons
pandem
influenza
threat
addit
direct
ultraperform
liquid
chromatographi
uplc
idm
method
report
rapid
accur
quantif
influenza
na
labelfre
msbase
method
also
report
simultan
identif
quantif
ha
na
influenza
vaccin
sampl
analyz
lcm
e
water
synapt
mass
spectromet
quantif
protein
labelfre
lcm
e
power
tool
method
altern
scan
low
collis
energi
elev
collis
energi
lcm
analysi
obtain
protein
ident
quantiti
singl
experi
quantif
base
experiment
data
show
signal
intens
proport
concentr
allow
amount
protein
mixtur
estim
lcm
e
util
parallel
multiplex
fragment
peptid
precursor
simultan
fragment
throughout
chromatograph
srid
assay
use
year
quantit
potenc
method
throughout
world
despit
issu
regard
variabl
avail
standard
reagent
thu
even
though
new
method
like
hplc
mass
spectrometri
develop
take
time
method
adopt
worldwid
next
influenza
pandem
predict
health
author
pandem
prepared
effort
includ
effort
ensur
expedit
avail
pandem
vaccin
method
hplc
ms
abil
quantit
antigen
without
standard
refer
reagent
becom
cornerston
pandem
influenza
prepared
viral
genu
flaviviru
includ
dengu
viru
yellow
fever
viru
glycosyl
predomin
nglycan
high
mannosetyp
mainli
combin
complexand
hybridtyp
glycan
studi
provid
import
new
insight
role
glycan
dengu
virushost
cell
interact
separ
studi
accur
quantit
express
four
viral
particl
tetraval
dengu
vaccin
cyd
perform
use
target
ms
select
reaction
monitor
srm
mode
studi
describ
orthogon
quantit
strategi
target
ms
srm
mode
demonstr
variabl
ms
method
low
assay
linear
nmoll
base
report
method
perform
could
use
releas
futur
batch
tetraval
dengu
vaccin
ebola
data
present
demonstr
nglycan
pattern
similar
gp
oglycan
pattern
remark
differ
gp
five
ebola
virus
studi
serv
foundat
futur
ebola
viral
entri
immunogen
studi
improv
convent
approach
absolut
quantit
ebola
viruslik
particl
evlp
isotop
dilut
fullscan
liquid
chromatographyhighresolut
mass
spectrometri
method
develop
use
ultim
hplc
orbitrap
elit
hybrid
ion
traporbitrap
mass
spectromet
report
ms
quantit
method
provid
mean
rapidli
determin
evlp
batch
qualiti
base
upon
quantit
antigen
also
ensur
adequ
preclinicalclin
dose
chikungunya
mosquitoborn
viral
diseas
endem
africa
southeast
asia
also
recent
emerg
caribbean
current
drug
vaccin
avail
treatment
prevent
name
chikungunya
deriv
makond
word
mean
becom
contort
describ
stoop
appear
suffer
joint
pain
arthralgia
msbase
approach
use
perform
physicochem
character
vaccin
one
studi
research
use
lcm
character
glycosyl
lysin
residu
anoth
studi
lcm
method
use
determin
rel
reactiv
lysin
residu
crm
determin
amino
acid
suscept
conjug
lcm
also
use
quantifi
vaccin
first
vaccin
develop
revers
vaccinolog
genomebas
approach
vaccin
develop
field
vaccin
veravelasco
et
al
quantifi
viral
f
g
protein
present
viral
particl
also
analyz
cellular
proteom
composit
niv
vaccin
candid
tradit
viral
particl
describ
pure
entiti
carri
viralderiv
protein
author
success
analyz
ratio
cellular
viral
protein
niv
vaccin
candid
use
lcmsm
west
nile
fever
flaviviru
caus
viral
infect
typic
spread
mosquito
date
vaccin
avail
prevent
west
nile
infect
partial
purifi
viruslik
particl
resolv
sdspage
coomassi
bluestain
band
correspond
env
protein
excis
gel
destain
analyz
ms
microcapillari
lcm
perform
use
lcq
deca
iontrap
mass
spectromet
thermo
finnigan
identifi
presenc
env
protein
viruslik
particl
help
develop
potenti
vaccin
supplement
batch
releas
test
ensur
product
within
specif
without
unwarr
modif
use
ms
techniqu
ensur
improv
qualiti
increas
safeti
clinic
trial
particip
conclus
evid
suggest
emerg
msbase
techniqu
advanc
field
vaccin
develop
